#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	19008	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2247	826.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1705	1705	T	1096	T	965	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	19008	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2247	826.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1439	1439	C	1159	C,T	1029,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	19008	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2247	826.4	0	HET	.	.	.	C199T	.	199	199	C	454	454	C	1014	C,T	649,221	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	35192	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3509	979.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1609	1609	A	1044	A	971	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	35192	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3509	979.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2243	2243	C	1071	C	959	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	35192	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3509	979.0	1	SNP	n	A2045G	1	A2045G	SNP	2045	2045	A	2317	2317	G	1203	G	1073	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	35192	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3509	979.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	2869	2869	C	1092	C	942	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	271	1324	folP	855	855	100.0	folP.l15.c4.ctg.1	1610	79.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1046	1048	AGC	142;142;142	A;G;C	130;130;130	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	271	1324	folP	855	143	100.0	folP.l15.c4.ctg.2	246	2.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3170	gyrA	2751	2751	99.96	gyrA.l6.c17.ctg.1	3359	90.9	1	SNP	p	S91F	1	.	.	271	273	TTC	543	545	TTC	102;102;101	T;T;C,G	90;90;88,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3170	gyrA	2751	2751	99.96	gyrA.l6.c17.ctg.1	3359	90.9	1	SNP	p	G95N	0	.	.	283	285	GGC	555	557	GGC	108;109;108	G;G;C	98;100;99	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3170	gyrA	2751	2751	99.96	gyrA.l6.c17.ctg.1	3359	90.9	1	SNP	p	D95G	1	.	.	283	285	GGC	555	557	GGC	108;109;108	G;G;C	98;100;99	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	982	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1371	69.4	1	SNP	p	G45D	0	.	.	133	135	GGC	549	551	GGC	123;126;125	G;G;C	112;115;114	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	698	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1144	59.6	0	.	n	.	0	A197.	DEL	197	197	A	649	649	A	141	A	133	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	3016	parC	2304	2304	99.87	parC.l15.c30.ctg.1	3063	95.0	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1486	1488	GTC	106;107;107	G;T;C	95;95;96	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	3016	parC	2304	2304	99.87	parC.l15.c30.ctg.1	3063	95.0	1	SNP	p	D86N	0	.	.	256	258	GAC	592	594	GAC	134;134;134	G;A;C	126;122;127	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	3016	parC	2304	2304	99.87	parC.l15.c30.ctg.1	3063	95.0	1	SNP	p	R87I	0	.	.	259	261	CGT	595	597	CGT	133;133;132	C;G;T	126;125;122	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	3016	parC	2304	2304	99.87	parC.l15.c30.ctg.1	3063	95.0	1	SNP	p	S87R	1	.	.	259	261	CGT	595	597	CGT	133;133;132	C;G;T	126;125;122	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	3016	parC	2304	2304	99.87	parC.l15.c30.ctg.1	3063	95.0	1	SNP	p	R87W	0	.	.	259	261	CGT	595	597	CGT	133;133;132	C;G;T	126;125;122	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	3016	parC	2304	2304	99.87	parC.l15.c30.ctg.1	3063	95.0	1	SNP	p	S88P	0	.	.	262	264	TCC	598	600	TCC	132;134;131	T;C;C	123;126;122	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	2714	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2841	91.6	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1470	1472	TGC	124;126;127	T;G;C	109;109;112	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	2714	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2841	91.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1680	1682	GGC	75;75;75	G;G;C	72;70;71	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3090	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2362	125.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1186	1188	GCA	202;202;205	G;C;A	176;177;179	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3090	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2362	125.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1189	1191	ATC	198;197;198	A;T;C	176;176;176	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3090	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2362	125.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1201	1203	GTG	195;194;193	G;T;G	173;170;172	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3090	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2362	125.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1201	1203	GTG	195;194;193	G;T;G	173;170;172	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3090	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2362	125.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1705	1707	ACC	123;123;122	A;C;C	114;114;113	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3090	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2362	125.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1759	1761	GCG	79;77;78	G;C;G	78;76;77	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3090	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2362	125.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1759	1761	GCG	79;77;78	G;C;G	78;76;77	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3090	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2362	125.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1882	1884	GGC	44;45;44	G;G;C	44;45;43	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3090	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2362	125.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1891	1893	GGC	37;36;36	G;G;C	37;36;36	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3090	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2362	125.8	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1909	1911	TCG	47;47;49	T,G;C;G	40,1;44;44	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6084	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	2788	209.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1395	1397	CCG	95;94;95	C;C;G	91;90;89	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1454	porA	1146	1146	99.56	porA.l6.c30.ctg.1	1638	85.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	483	483	C	82	C	77	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	188	porB1a	984	284	90.28	porB1a.l15.c30.ctg.2	414	18.4	0	.	p	.	0	H217N	NONSYN	649	651	CAT	155	157	AAT	5;6;6	A;A;T	5;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	188	porB1a	984	284	90.28	porB1a.l15.c30.ctg.2	414	18.4	0	.	p	.	0	D218N	NONSYN	652	654	GAT	158	160	AAT	6;6;6	A;A;T	6;6;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	188	porB1a	984	284	90.28	porB1a.l15.c30.ctg.2	414	18.4	0	.	p	.	0	V226A	NONSYN	676	678	GTA	182	184	GCA	13;13;13	G;C;A	13;13;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	188	porB1a	984	284	90.28	porB1a.l15.c30.ctg.2	414	18.4	0	.	p	.	0	.	MULTIPLE	700	702	ACT	205	207	GTA	16;17;17	G;T;A	16;17;17	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	188	porB1a	984	284	90.28	porB1a.l15.c30.ctg.2	414	18.4	0	.	p	.	0	S236N	NONSYN	706	708	AGC	211	213	AAC	17;17;16	A;A;C	17;17;16	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	188	porB1a	984	284	90.28	porB1a.l15.c30.ctg.2	414	18.4	0	.	p	.	0	.	MULTIPLE	709	711	AAC	215	219	TGGCG	16;16;16;21;28	T;G;G;C;G	16;16;16;19;23	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	188	porB1a	984	284	90.28	porB1a.l15.c30.ctg.2	414	18.4	0	.	p	.	0	D238A	NONSYN	712	714	GAT	221	223	GCT	31;31;31	G;C;T	25;25;25	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	188	porB1a	984	284	90.28	porB1a.l15.c30.ctg.2	414	18.4	0	.	p	.	0	V258L	NONSYN	772	774	GTA	281	283	TTA	42;42;43	T;T;A	37;37;37	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	188	porB1a	984	284	90.28	porB1a.l15.c30.ctg.2	414	18.4	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	326	328	CAT	31;24;24	C;A;T	30;23;23	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	188	porB1a	984	284	90.28	porB1a.l15.c30.ctg.2	414	18.4	0	.	p	.	0	D274S	NONSYN	820	822	GAT	329	331	AGT	24;24;24	A;G;T	23;23;23	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	188	porB1a	984	284	90.28	porB1a.l15.c30.ctg.2	414	18.4	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	338	340	TAC	24;24;24	T;A;C	23;23;23	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2294	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1387	160.1	0	.	p	.	0	N38E	NONSYN	112	114	AAT	307	309	GAA	218;212;213	G;A;A	205;199;200	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2294	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1387	160.1	0	.	p	.	0	T106I	NONSYN	316	318	ACC	511	513	ATC	169;169;169	A;T;C	156;158;158	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2294	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1387	160.1	0	.	p	.	0	N134D	NONSYN	400	402	AAT	595	597	GAT	172;172;189	G;A;T	154;153;166	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2294	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1387	160.1	0	.	p	.	0	P175S	NONSYN	523	525	CCA	718	720	TCA	180;179;180	T;C;A	160;158;160	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2294	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1387	160.1	0	.	p	.	0	Y211F	NONSYN	631	633	TAC	826	828	TTC	183;182;177	T;T;C	157;158;156	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2294	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1387	160.1	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1177	1179	GCA	165;164;146	G;C;A	139;138;127	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2294	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1387	160.1	1	SNP	p	G120K	1	.	.	358	360	AAG	553	555	AAG	162;163;170	A;A;G	147;148;151	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2294	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1387	160.1	1	SNP	p	A121D	1	.	.	361	363	GAC	556	558	GAC	172;170;172	G;A;C	155;153;152	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2294	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1387	160.1	1	SNP	p	D121N	0	.	.	361	363	GAC	556	558	GAC	172;170;172	G;A;C	155;153;152	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8690	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	4474	188.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1774	1776	AAT	206;209;210	A;A;T	181;186;184	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	824	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	921	85.9	1	SNP	p	V57M	1	.	.	169	171	ATG	436	438	ATG	163;162;164	A;T;G	142;142;144	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
